Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes
01 juil. 2020 08h30 HE
|
Geron Corporation
Designation would provide 10-year period of marketing exclusivity in the European Union after product approvalPatients are currently enrolling in a Geron-sponsored Phase 3 clinical trial in lower risk...
Geron Announces Two Poster Presentations at Upcoming American Society of Hematology Annual Meeting
06 nov. 2019 09h18 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts related to imetelstat, the Company’s first-in-class telomerase inhibitor,...
Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
10 oct. 2019 17h30 HE
|
Geron Corporation
MENLO PARK, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate...
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis
30 sept. 2019 16h19 HE
|
Geron Corporation
MENLO PARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation...
Geron to Announce Second Quarter Financial Results on August 1, 2019
25 juil. 2019 08h00 HE
|
Geron Corporation
MENLO PARK, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2019 financial results after the market closes on...
Sermonix Receives FDA Fast Track Designation for Investigational Drug Lasofoxifene
28 mai 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, May 28, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development of female-specific oncology products, today...
Geron Announces Two Presentations on Imetelstat at Upcoming European Hematology Association Annual Congress
16 mai 2019 09h05 HE
|
Geron Corporation
MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts containing clinical data and analyses related to imetelstat, the Company’s...
Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer
17 avr. 2019 07h35 HE
|
Intensity Therapeutics Inc
WESTPORT, Conn., April 17, 2019 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers...
uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
08 avr. 2019 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 08, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
Geron Reports Updated Results from Phase 2 Portion of IMerge at the 60th American Society of Hematology Annual Meeting
03 déc. 2018 06h00 HE
|
Geron Corporation
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that updated results from Part 1 of IMerge, the Phase 2 portion of a Phase 2/3 clinical trial...